CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $276.2 million in its fourth quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.47 per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $2.25 per share.

The RNA interference drug developer posted revenue of $71.7 million in the period, beating Street forecasts. Six analysts surveyed by Zacks expected $71.3 million.

For the year, the company reported that its loss widened to $886.1 million, or $8.11 per share. Revenue was reported as $219.8 million.

Alnylam shares have climbed roughly 6% since the beginning of the year. The stock has risen 48% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Automated Insights, source Associated Press News